BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AdipoGenix, Inc. Achieves Third Milestone In Collaboration With Johnson & Johnson (JNJ)


3/14/2006 11:53:02 AM

BOSTON, March 14 /PRNewswire/ -- AdipoGenix Inc., a biopharmaceutical company developing small molecule therapies for obesity, type 2 diabetes and associated morbidities, today announced the achievement of its third milestone in the Company's drug discovery collaboration with Johnson & Johnson (J&J).

In November 2002, AdipoGenix and J&J entered a drug discovery collaboration in which AdipoGenix has utilized its proprietary human fat cell- based technologies for discovering compounds that reduce the fat content of human fat cells from J&J's compound collection. In addition, AdipoGenix has been characterizing the mechanisms of action and identifying molecular targets for the highest priority of the active compounds that were discovered. The milestone announced today was for the successful identification of the molecular target for one of J&J's active compounds that was discovered earlier in the collaboration. Financial details were not disclosed.

"This is the third milestone that we have achieved in our alliance with J&J, and this achievement provides further validation for our capability to discover compounds that have a beneficial effect on fat cells, and to define mechanisms and molecular targets for active compounds," said Ed Cannon, Ph.D., CEO of AdipoGenix.

Monique Berwaer, Principal Scientist and Metabolic Diseases Team Leader, Johnson & Johnson Pharmaceutical Research and Development commented, "AdipoGenix's human fat cell-based discovery technology is unique and we believe that treating obesity by targeting human fat with pharmaceuticals that reduce fat content is distinctive and an important new approach for combating the growing obesity epidemic."

AdipoGenix Technology

AdipoGenix's core assets and capabilities include a proprietary and diverse collection of human fat cell precursors from all relevant fat deposits, a high-throughput discovery technology for differentiating these precursor cells to form mature human fat cells and identifying compounds that reduce the fat content of human fat cells, a portfolio of assays and pharmacologic tools to identify the mechanism of action and molecular targets for active compounds identified, and proprietary lead compounds. With this comprehensive approach, AdiopGenix has been able to rapidly identify non-toxic small molecule compounds that target the pathological tissue (fat) from the relevant organism (humans) and produce the desired therapeutic outcome (less fat).

About AdipoGenix Inc.

AdipoGenix is a Boston-based biopharmaceutical company developing pharmaceuticals that target human fat tissue to treat obesity and its co- morbidities, including diabetes and cardiovascular disease. Through its proprietary human fat cell-based technology, AdipoGenix identifies nontoxic, small molecule compounds that reduce the fat content in human fat tissue, which is expected to provide therapeutic benefit for these important diseases.

On the Net: http://www.AdipoGenix.com Contacts: Ed Cannon Kari Watson President and CEO MacDougall Biomedical Communications AdipoGenix Inc. (508) 647-0209 617-638-6394 kwatson@macbiocom.com

AdipoGenix Inc.

CONTACT: Ed Cannon, President and CEO of AdipoGenix Inc., +1-617-638-6394; or Kari Watson of MacDougall Biomedical Communications,+1-508-647-0209, kwatson@macbiocom.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES